Group BD15 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 15 Î1⁄4g (0.5 ml)	Group BD5 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 5 Î1⁄4g (0.5ml) , Group BD10 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 10 Î1⁄4g (0.5 ml)	The time taken for complete sensory recovery	2069	2251	The time taken for complete sensory recovery in Group D5-319.83 ± 61.41, Group D10-336.13 ± 61.38, and Group D15-415.20 ± 96.6, which is statistically highly significant (P = 0.000).
Group BD15 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 15 Î1⁄4g (0.5 ml)	Group BD5 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 5 Î1⁄4g (0.5ml) , Group BD10 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 10 Î1⁄4g (0.5 ml)	The time taken for two-segment sensory regression	1926	2068	The time taken for two-segment sensory regression Group D5-96.66 ± 33.67, Group D10-116.80 ± 36.27, and Group D15 120.96 ± 30.24, (P = 0.014).
Group BD15 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 15 Î1⁄4g (0.5 ml), Group BD5 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 5 Î1⁄4g (0.5ml) , Group BD10 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 10 Î1⁄4g (0.5 ml)	baseline	mean arterial pressure (MAP) falls	14468	14742	MAP falls significantly at 30th, 45th, and 60th min from basal rate within the groups, we have noticed hypotension in 4 (13.3%) patients in Group D5, 6 (20.0%) patients in Group D10, 13 (43.3%) patients in Group D15, which is statistically significant (P = 0.020) [Table 3].
Group BD15 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 15 μg (0.5 ml), Group BD5 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 5 μg (0.5ml) , Group BD10 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 10 μg (0.5 ml)	baseline	Heart rate falls	14216	14467	The HR fall significantly at 105 and 120 min from basal rate within groups, we noticed bradycardia in 3 (10.0%) patients among Group D5, 4 (13.3%) patients in Group D10, 10 (33.3%) patients in Group D15, which is statistically significant (P = 0.044).
Group BD15 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 15 Î1⁄4g (0.5 ml)	Group BD5 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 5 Î1⁄4g (0.5ml) , Group BD10 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 10 Î1⁄4g (0.5 ml)	Time for rescue analgesia	2252	2422	Time for rescue analgesia in Group D5-377.46 ± 60.05, in Group D10-401.60 ± 61.11, and in Group D15-517.96 ± 97.30, which is statistically highly significant (P < 0.000).
Group BD15 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 15 μg (0.5 ml)	Group BD5 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 5 μg (0.5 ml), Group BD10 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 10 μg (0.5 ml)	The onset time of sensory block	1773	1925	The onset time of sensory block in Group D5-2.76 ± 1.32, Group D10-2.45 ± 1.50, and Group D15-1.86±0.93, which is statistically significant (P = 0.025).
